CECelina Eckfeld

Celina Eckfeld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Celina Eckfeld has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subclonal MECOM rearrangements in myeloid neoplasms: enriched for TP53 mutations and adverse outcome

    by Celina Eckfeld, Anna Stengel, Sandra Huber, Sophia Prohaska, Manja Meggendorfer, Torsten Haferlach, Isolde Summerer

  • Open Access

    Data from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Tumor-derived protein tissue inhibitor of metalloproteinases-1 (TIMP1) correlates with poor prognosis in many cancers, including highly lethal pancreatic ductal adenocarcinoma (PDAC). The noncanonical signaling activity of TIMP1 is emerging as one basis for its contribution to cancer progression. However, TIMP1–triggered progression-related biological processes are largely unknown. Formation of neutrophil extracellular traps (NET) in the tumor microenvironment is known to drive progression of PDAC, but factors or molecular mechanisms initiating NET formation in PDAC remain elusive. In this study, gene-set enrichment analysis of a human PDAC proteome dataset revealed that TIMP1 protein expression most prominently correlates with neutrophil activation in patient-derived tumor tissues. TIMP1 directly triggered formation of NETs in primary human neutrophils, which was dependent on the interaction of TIMP1 with its receptor CD63 and subsequent ERK signaling. In genetically engineered PDAC-bearing mice, TIMP1 significantly contributed to NET formation in tumors, and abrogation of TIMP1 or NETs prolonged survival. In patient-derived PDAC tumors, NETs predominantly colocalized with areas of elevated TIMP1 expression. Furthermore, TIMP1 plasma levels correlated with DNA-bound myeloperoxidase, a NET marker, in the blood of patients with PDAC. A combination of plasma levels of TIMP1 and NETs with the clinically established marker CA19–9 allowed improved identification of prognostically distinct PDAC patient subgroups. These observations may have a broader impact, because elevated systemic levels of TIMP1 are associated with the progression of a wide range of neutrophil-involved inflammatory diseases.Significance:These findings highlight the prognostic relevance of TIMP1 and neutrophil extracellular traps in highly lethal pancreatic cancer, where a noncanonical TIMP1/CD63/ERK signaling axis induces NET formation.

  • Open Access

    Supplementary Figures and Tables from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Supplementary Figures S1 - S9 Table S1 and S2

  • Open Access

    Supplementary Data from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Supplementary Material and Methods

  • Open Access

    Supplementary Data from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Supplementary Material and Methods

  • Open Access

    Supplementary Figures and Tables from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Supplementary Figures S1 - S9 Table S1 and S2

  • Open Access

    Data from TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Tumor-derived protein tissue inhibitor of metalloproteinases-1 (TIMP1) correlates with poor prognosis in many cancers, including highly lethal pancreatic ductal adenocarcinoma (PDAC). The noncanonical signaling activity of TIMP1 is emerging as one basis for its contribution to cancer progression. However, TIMP1–triggered progression-related biological processes are largely unknown. Formation of neutrophil extracellular traps (NET) in the tumor microenvironment is known to drive progression of PDAC, but factors or molecular mechanisms initiating NET formation in PDAC remain elusive. In this study, gene-set enrichment analysis of a human PDAC proteome dataset revealed that TIMP1 protein expression most prominently correlates with neutrophil activation in patient-derived tumor tissues. TIMP1 directly triggered formation of NETs in primary human neutrophils, which was dependent on the interaction of TIMP1 with its receptor CD63 and subsequent ERK signaling. In genetically engineered PDAC-bearing mice, TIMP1 significantly contributed to NET formation in tumors, and abrogation of TIMP1 or NETs prolonged survival. In patient-derived PDAC tumors, NETs predominantly colocalized with areas of elevated TIMP1 expression. Furthermore, TIMP1 plasma levels correlated with DNA-bound myeloperoxidase, a NET marker, in the blood of patients with PDAC. A combination of plasma levels of TIMP1 and NETs with the clinically established marker CA19–9 allowed improved identification of prognostically distinct PDAC patient subgroups. These observations may have a broader impact, because elevated systemic levels of TIMP1 are associated with the progression of a wide range of neutrophil-involved inflammatory diseases.Significance:These findings highlight the prognostic relevance of TIMP1 and neutrophil extracellular traps in highly lethal pancreatic cancer, where a noncanonical TIMP1/CD63/ERK signaling axis induces NET formation.

  • Open Access

    TIMP-1 is a novel ligand of Amyloid Precursor Protein and triggers a proinflammatory phenotype in human monocytes

    by Celina Eckfeld, Benjamin Schoeps, Daniel Häußler, Julian Frädrich, Felix Bayerl, Jan Philipp Böttcher, Percy Knolle, Simone Heisz, Olga Prokopchuk, Hans Hauner, et al.

    The emerging cytokine tissue inhibitor of metalloproteinases-1 (TIMP-1) correlates with the progression of inflammatory diseases, including cancer. However, the effects of TIMP-1 on immune cell activation and underlying molecular mechanisms are largely unknown. Unbiased ligand-receptor-capture-screening revealed TIMP-1-interaction with Amyloid Precursor Protein (APP) family members, namely APP and Amyloid Precursor-like Protein-2 (APLP2), which was confirmed by pull-down assays and confocal microscopy. We found that TIMP-1 triggered glucose uptake and proinflammatory cytokine expression in human monocytes. In cancer patients, TIMP-1 expression positively correlated with proinflammatory cytokine expression and processes associated with monocyte activation. In pancreatic cancer, TIMP-1 plasma levels correlated with the monocyte activation marker sCD163, and the combined use of both clinically accessible plasma proteins served as a powerful prognostic indicator. Mechanistically, TIMP-1 triggered monocyte activation by its C-terminal domain and via APP as demonstrated by in vitro interference, in silico docking, and the employment of recombinant TIMP-1 variants. Identification of TIMP-1 as a trigger of monocyte activation opens new therapeutic perspectives for inflammatory diseases.


  • Open Access

    TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer

    by Chris D. Hermann, Benjamin Schoeps, Celina Eckfeld, Enkhtsetseg Munkhbaatar, Lukas Kniep, Olga Prokopchuk, Nils Wirges, Katja Steiger, Daniel Häußler, Percy Knolle, et al.

    Sex disparity in cancer is so far inadequately considered, and components of its basis are rather unknown. We reveal that male versus female pancreatic cancer (PC) patients and mice show shortened survival, more frequent liver metastasis, and elevated hepatic metastasis-promoting gene expression. Tissue inhibitor of metalloproteinases 1 (TIMP1) was the secreted factor with the strongest male-biased expression in patient-derived pancreatic tumors. Male-specific up-regulation of systemic TIMP1 was demonstrated in PC mouse models and patients. Using TIMP1-competent and TIMP1-deficient PC mouse models, we established a causal role of TIMP1 in determining shortened survival and increased liver metastasis in males. Observing TIMP1 expression as a risk parameter in males led to identification of a subpopulation exhibiting increased TIMP1 levels (T1HI males) in both primary tumors and blood. T1HI males showed increased risk for liver metastasis development not only in PC but also in colorectal cancer and melanoma. This study reveals a lifestyle-independent sex disparity in liver metastasis and may open new avenues toward precision medicine.


  • Open Access

    TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer

    by Benjamin Schoeps, Celina Eckfeld, Olga Prokopchuk, Jan Böttcher, Daniel Häußler, Katja Steiger, Ihsan Ekin Demir, Percy Knolle, Oliver Soehnlein, Dieter E. Jenne, et al.

    Tumor-derived protein tissue inhibitor of metalloproteinases-1 (TIMP1) correlates with poor prognosis in many cancers, including highly lethal pancreatic ductal adenocarcinoma (PDAC). The noncanonical signaling activity of TIMP1 is emerging as one basis for its contribution to cancer progression. However, TIMP1–triggered progression-related biological processes are largely unknown. Formation of neutrophil extracellular traps (NET) in the tumor microenvironment is known to drive progression of PDAC, but factors or molecular mechanisms initiating NET formation in PDAC remain elusive. In this study, gene-set enrichment analysis of a human PDAC proteome dataset revealed that TIMP1 protein expression most prominently correlates with neutrophil activation in patient-derived tumor tissues. TIMP1 directly triggered formation of NETs in primary human neutrophils, which was dependent on the interaction of TIMP1 with its receptor CD63 and subsequent ERK signaling. In genetically engineered PDAC-bearing mice, TIMP1 significantly contributed to NET formation in tumors, and abrogation of TIMP1 or NETs prolonged survival. In patient-derived PDAC tumors, NETs predominantly colocalized with areas of elevated TIMP1 expression. Furthermore, TIMP1 plasma levels correlated with DNA-bound myeloperoxidase, a NET marker, in the blood of patients with PDAC. A combination of plasma levels of TIMP1 and NETs with the clinically established marker CA19–9 allowed improved identification of prognostically distinct PDAC patient subgroups. These observations may have a broader impact, because elevated systemic levels of TIMP1 are associated with the progression of a wide range of neutrophil-involved inflammatory diseases.Significance: These findings highlight the prognostic relevance of TIMP1 and neutrophil extracellular traps in highly lethal pancreatic cancer, where a noncanonical TIMP1/CD63/ERK signaling axis induces NET formation.